# GC Cell

Source: https://onco.cc/companies/gc-cell/  
OnCo record `gc-cell` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GC Cell is a South Korean cell therapy company whose autologous cytokine-induced killer cell product Immuncell-LC has been approved in Korea since 2007 as adjuvant treatment after liver cancer surgery.

## Summary

GC Cell, part of the GC (Green Cross) group and listed in Korea, was formed in 2021 from Green Cross Cell and Green Cross LabCell. Its longest-standing product is Immuncell-LC, autologous cytokine-induced killer cells given after resection of hepatocellular carcinoma, approved in South Korea in 2007 and supported by a phase 3 trial showing longer recurrence-free survival; the company also develops CAR-T and NK cell therapies. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: GC Cell Corporation; Green Cross Cell; GC Cell Corp.
- Tags: ctgov-sponsor
- HQ: Yongin
- Type: cell-therapy
- Website: https://www.gccell.com

## Sources

- Official website: https://www.gccell.com
- ClinicalTrials.gov: trials led by GC Cell: https://clinicaltrials.gov/search?lead=GC%20Cell

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)

---
JSON: https://onco.cc/api/v1/entities/gc-cell.json